Gilead HCV Sales Decline In US, But Offset By Global Growth
This article was originally published in The Pink Sheet Daily
Executive Summary
A blockbuster launch in Japan and significant sales growth in Europe for Harvoni and Sovaldi outstrip the revenue declines seen in the US, which the firm attributes partly to a sharp drop-off in HCV treatment by the VA.